← Back to search
THE GENERAL HOSPITAL CORPORATION
BOSTON, MA, 02114
UnclaimedClaim this profile (free)
Other Than Small Business
Prime contracting experience
25 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COORDINATION CENTER | 75N92022D00014USAspending | $3,580,000 | Sep 17, 2026 | Sep 23, 2026 – Sep 22, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | RADX INNOVATION FUNNEL FOR HIV DIAGNOSTICS - COORDINATION CENTER | 75N92022D00014USAspending | $594,106 | Sep 3, 2026 | Jun 3, 2024 – May 27, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | INNOVATION FUNNEL FOR FETAL MONITORING CHALLENGE - COORDINATION CENTER | 75N92022D00014USAspending | $566,750 | Sep 2, 2026 | Aug 3, 2023 – Nov 2, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | POCTRN SUPPORT - COORDINATION CENTER | 75N92022D00014USAspending | $2,828,856 | Aug 26, 2026 | Sep 7, 2023 – Sep 6, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE AWARD FOR PEDIATRIC PROTON AND PHOTON THERAPY COMPARISON COHORT COORDINATING CENTER. THE CONTRACTOR SHALL ASSEMBLE EXISTING DATA FROM MEDICAL RECORDS FOR A GROUP OF PEDIATRIC CANCER PATIENTS WHO RECEIVED PROTON OR PHOTON THERAPY. THE OBJECTIVE I | — | $624,994 | Aug 21, 2026 | Sep 15, 2024 – Mar 14, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COORDINATION CENTER | 75N92022D00014USAspending | $1,493,050 | Aug 6, 2026 | Sep 30, 2024 – Sep 29, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) RADX ADMINISTRATIVE SUPPORT - COORDINATION CENTER | 75N92022D00014USAspending | $5,328,658 | Aug 3, 2026 | Dec 16, 2022 – Jun 30, 2027 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | DARPA RESEARCH PROGRAM SUPPORT SERVICES | HR001124A0003USAspending | $288,230 | Jul 17, 2026 | Oct 1, 2025 – Dec 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | MASSACHUSETTS GENERAL HOSPITAL:1105940 [22-000155] | — | $1,283,262 | Jul 15, 2026 | Jul 13, 2022 – Jul 14, 2027 |
| Prime | Department of Health and Human Services Centers for Disease Control and Prevention | GENERAL HOSPITAL CORPORATION | — | $2,333,872 | Jun 9, 2026 | Sep 30, 2024 – Sep 29, 2026 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | DARPA COMMERCIAL ACCELERATOR SUPPORT SERVICES | HR001124A0003USAspending | $300,068 | Mar 5, 2026 | Mar 9, 2026 – Aug 30, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | ENHANCE FDA SOURCE MODEL BY INCORPORATING AND ANALYZING STATE AND REGIONAL-LEVEL DATA BAA- FY24C3DP4 | — | $268,667 | Feb 4, 2026 | Sep 25, 2024 – Apr 4, 2025 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | DARPA RESEARCH PROGRAM SUPPORT SERVICES | HR001124A0003USAspending | $300,068 | Jan 13, 2026 | Jun 9, 2025 – Dec 18, 2026 |
| Prime | Department of Defense U.S. Special Operations Command | COMPREHENSIVE BRAIN HEALTH AND TRAUMA (COMBHAT) PROGRAM - SOF TBI PILOT PROGRAM | — | $8,000,000 | Dec 17, 2025 | Sep 30, 2023 – Sep 29, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) MATERNAL HEALTH RADX INNOVATION FUNNEL | 75N92022D00014USAspending | $399,558 | Dec 10, 2025 | Sep 1, 2022 – Apr 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) HIV/AIDS RADX INNOVATION FUNNEL | 75N92022D00014USAspending | $298,795 | Dec 10, 2025 | Sep 1, 2022 – Aug 31, 2024 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | DARPA COMMERCIAL ACCELERATORS SUPPORT SERVICES | HR001124A0003USAspending | $543,513 | Oct 6, 2025 | Oct 8, 2025 – Sep 30, 2026 |
| Prime | Department of Health and Human Services Centers for Disease Control and Prevention | HARNESSING ELECTRONIC HEALTH RECORDS FOR SURVEILLANCE OF LYME DISEASE | — | $1,009,764 | May 7, 2025 | Sep 29, 2023 – Sep 28, 2024 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | DARPA COMMERCIAL ACCELERATORS SUPPORT | HR001124A0003USAspending | $527,043 | Mar 6, 2025 | Sep 12, 2024 – Sep 11, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) INNOVATION FUNNEL COORDINATION CENTER FOR RADX INNOVATION FUNNEL FOR COVID-19 | 75N92022D00014USAspending | $8,878,381 | Jun 24, 2024 | Sep 21, 2022 – Sep 22, 2026 |
| Prime | Department of Health and Human Services Centers for Disease Control and Prevention | RESEARCH AND DEVELOPMENT OF SERUM SAMPLES | — | $263,466 | Feb 6, 2024 | Sep 25, 2023 – Dec 24, 2024 |
| Prime | Department of Health and Human Services Indian Health Service | HOSPITALIST, FAMILY MEDICINE, AND/OR INTERNAL MEDICINE PHYSICIAN SERVICES | — | $2,087,605 | Sep 19, 2023 | Dec 10, 2021 – Jul 31, 2023 |
| Prime | Department of Defense Department of the Army | IGF::OT::IGF JW160063 RTCDS R&D | — | $5,730,675 | Sep 8, 2023 | Sep 25, 2017 – Dec 29, 2022 |
| Prime | Department of Defense Defense Threat Reduction Agency | BREAKING THE CODE OF HUMORAL CORRELATES OF PROTECTION AGAINST EBOLA | — | $1,652,391 | Aug 24, 2023 | Dec 14, 2021 – Jun 12, 2024 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | CLINICAL TRIAL SUPPORT SERVICES | 36C24118D0002USAspending | $355,226 | Feb 23, 2023 | Jun 20, 2020 – Jun 19, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
33 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | BARDA ACCELERATOR NETWORK 2.0 - SPECIAL POPULATIONS HUB 30008824-03 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541990 Parent award performance state: DC Parent award description: BARDA ACCELERATOR NETWORK 2.0, SPECIAL POPULATIONS HUB - CHILDREN'S NATIONAL View parent award on USAspending | — | $69,962 | Jun 9, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | AS PART OF THE PROPOSED STUDY LED BY DR. MCCABE, THE MGH SITE, LED BY DR. TIMOTHY WILENS WILL BE UTILIZING ALREADY COLLECTED DATA AS WELL AS ONGOING LONGITUDINAL DATA THAT IS BEING COLLECTED ALREADY AS PART OF THE NIH FUNDED HEAL INITIATIVE GRANT TO MGH. SUBK00022386 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541714 Parent award performance state: MI Parent award description: A MOSAIC APPROACH FOR UNDERSTANDING STIMULANT AND OPIOID USE AND USE DISORDER TRAJECTORIES AND ASSOCIATED CONSEQUENCES IN US ADULTS View parent award on USAspending | — | $231,024 | Feb 19, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM
THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109785.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $239,623 | Oct 9, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT A: VACCINE CENTER SUB00002149 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: GA Parent award description: COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU View parent award on USAspending | — | $117,900 | Oct 7, 2024 | — – — |
| Subcontractor | Department of Energy | MASSACHUSETTS GENERAL HOSPITAL-STANDALONE-ITEM LEVEL-R AND D CW45560 Parent award context Parent award agency: Department of Energy · Department of Energy Parent award NAICS: 561210 Parent award performance state: NM Parent award description: IGF::CL::IGF COMPETITION FOR MANAGEMENT AND OPERATION OF LOS ALAMOS NATIONAL LABORATORY View parent award on USAspending | — | $709,155 | Aug 15, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM
THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109786.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $554,666 | Mar 5, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, PROTEOMICS, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
OPTION 3 ACTIVITIES: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN THE NHP MODEL OF TB
SCRI HAS WORKED WITH DR. RYAN MCNAMARA AT THE RAGON INSTITUTE TO DEVELOP A WORKPLAN FOR THE SYSTEM SEROLOGY ENDPOINTS FOR BOTH CLINICAL AND PRECLINICAL EVALUATIONS. WE HAVE CONFIRMED THAT A LIST OF 207 M.TB ANTIGENS THAT WERE RECENTLY PUBLISHED ARE NOT PROPRIETARY TO RAGON AND ARE AN APPROPRIATE SET FOR OUR INVESTIGATIONS.
TASK 3.7 COMPARE IMMUNE PROFILES IN NHP, SMALL ANIMAL MODELS AND HUMANS TO IDENTIFY CORRELATES OF PROTECTION.
SUBTASK 3.7.1 EVALUATE HUMORAL IMMUNITY AS A VACCINE-INDUCED CORRELATE OF PROTECTION USING SYSTEMS SEROLOGY IN THE NHP MODEL.
SEVERAL EFFECTOR FUNCTIONS BASED ON THE FC PORTION OF THE ANTIBODY CAN CONTRIBUTE TO THE CLEARANCE OF ORGANISMS, INCLUDING COMPLEMENT ACTIVITY, ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS (ADCP), ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC), ANTIBODY-DEPENDENT CYTOKINE AND CHEMOKINE SECRETION. SYSTEMS SEROLOGY ANALYSIS WILL BE USED TO EVALUATE ANTIBODY EFFECTOR FUNCTIONS INCLUDING NK CELL ACTIVATION, ADCP, AND ADCC. THESE ASSAYS CAPTURE OVER 100 BIOPHYSICAL AND FUNCTIONAL CHARACTERISTICS OF POLYCLONAL ABS, INCLUDING CYTOLYTIC ACTIVITY, PHAGOCYTIC TARGET CLEARANCE, CYTOKINE SECRETION, AND IMMUNOMODULATOR RELEASE. THIS SUITE OF FUNCTIONAL ASSAYS WILL BE UTILIZED TO BROADLY DEFINE THE FC PROFILES OF ID93- AND BCG-SPECIFIC ABS. FOR ALL FUNCTIONAL ASSAYS, THE FUNCTIONAL ACTIVITY OF ABS WILL BE ASSESSED AGAINST ID93, PPD, INFLUENZA HEMAGGLUTININ (CONTROL), EBOLA VIRUS GLYCOPROTEIN (NEGATIVE CONTROL). ALL ANTIGENS WILL BE BIOTINYLATED AND ATTACHED TO STREPTAVIDIN-FLUORESCENT BEADS (THERMO FISHER). SIGMA INTRAVENOUS IG WILL BE USED AS A POSITIVE CONTROL. SAMPLES RECEIVED FROM COLLABORATORS ON THIS PROJECT (MOUSE, GUINEA PIG, NHP AND HUMAN) WILL BE USED TO CARRY OUT THE SYSTEMS SEROLOGY APPROACH DETAILED BELOW.
SYSTEMS SEROLOGY CAPTURES LARGE NUMBERS OF DISTINCT ANTIGEN-SPECIFIC SERUM BASED ANTIBODY PROFILE FEATURES THAT COMPREHENSIVELY AND OBJECTIVELY PROBES THE ANTIGEN-SPECIFIC FC-ANTIBODY-OME AT UNPRECEDENTED DEPTH. DISPARATE 53 DATA POINTS WILL BE INTEGRATED AND A SPECTRUM OF COMPUTATIONAL METHODS FOR CONSTRUCTING MULTI-VARIATE MODELS AND THEN APPLIED TO ASCERTAIN PREDICTIVE RELATIONSHIPS BETWEEN COMBINATIONS OF SYSTEM VARIABLES (STRUCTURE:FUNCTION, TRANSFER, ETC.) TO DEFINE NOVEL AND OFTEN UNEXPECTED INSIGHTS INTO THE ANTIBODY CHARACTERISTICS THAT DRIVE UNIQUE AND DISTINCT BIOLOGICAL OUTCOMES. THESE ANALYTICAL METHODS INCLUDE NON-NEGATIVE MATRIX FACTORIZATION, SELF-ORGANIZING MAPS, MULTI-LINEAR REGRESSION, PARTIAL LEAST-SQUARES DISCRIMINATION, DECISION TREES, AND RANDOM FORESTS AMONG OTHERS, INCLUDING FEATURE REDUCTION WHEN NECESSARY FOR CONSTRAINING THE NUMBER OF REGULATORY VARIABLES TO HELP PREVENT MODEL OVER-FITTING. TWO SPECIFIC APPROACHES WILL BE UTILIZED TO DEFINE IMMUNE RESPONSE AND IMMUNE CORRELATES OF PROTECTION ASSOCIATED CHANGES USING BOTH €œFLAT€Ͽ½ AND €œHIERARCHICAL€Ͽ½ FRAMEWORKS. IN THE €œFLAT€Ͽ½ FRAMEWORK, A SINGLE-LEVEL MODEL WILL BE UTILIZED €€Œ EXPLOITED EACH DATA POINT AS AN INDEPENDENT VARIABLE. THIS AGNOSTIC APPROACH ENABLES THE UNBIASED IDENTIFICATION OF INDIVIDUAL ANTIBODY FC-FEATURES, INDEPENDENT OF THE ASSAY/CELL TYPE FROM WHICH THEY ARE DERIVED. THE €œHIERARCHICAL€Ͽ½ FRAMEWORK, IN CONTRAST, INCORPORATES ASSAY/CELL SPECIFIC INFORMATION FOR DATA AGGREGATION. THUS, A MULTI-LEVEL MODEL WILL BE USED TO DEFINE FUNCTIONAL ATTRIBUTES ENRICHED 13233SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $451,067 | Jan 31, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | RESEARCH - BASE FUNDING
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR
MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.
€¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND
HOSTING TRAINEES FROM COLLABORATING LABS.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA
SEQUENCING.
SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL:
€¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. 109786.5110779 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $1,583,068 | Jan 26, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | SUBRECIPIENT LAB WILL
PERFORM SYSTEMS
SEROLOGY ASSAYS TO
EVALUATE THE IMMUNE
RESPONSES
ELICITED IN 30 ADULTS IN
A CONTROLLED HUMAN
INFECTION MODEL (CHIM)
STUDY BEFORE AND AFTER
PERTUSSIS
CHALLENGE AND OVER
MULTIPLE TIME POINTS.
THESE ASSAYS WILL
INCLUDE ANTIBODY
BIOPHYSICAL PROFILING,
ANTIBODY DEPENDENT
CELLULAR PHAGOCYTOSIS
BY VARIOUS
PHAGOCYTES, ANTIBODY
MEDIATED CYTOTOXICITY,
ANTIBODY MEDIATED
COMPLEMENT
ACTIVATION, AND
ANTIBODY MEDIATED
ANTI-MICROBIAL ACTIVITY.
THE DATA
GENERATED FROM THESE
HIGH THROUGHPUT
STUDIES WILL THEN BE
ANALYZED USING
MACHINE LEARNING APPROACHES. 20974-KB 4970 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541690 Parent award performance state: MD Parent award description: BAA TOPIC 22.3 - SYSTEMS SEROLOGY AND CELLULAR MARKERS OF PROTECTION AGAINST PERTUSSIS IN A CONTROLLED HUMAN INFECTION MODEL View parent award on USAspending | — | $294,000 | Jan 11, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR) 2006187760 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: MD Parent award description: AWARD OF THE BASE TO HOPKINS FOR CEIRR CONTRACT 75N93021C00045. THIS CONTRACT WILL SUPPORT THE NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR). View parent award on USAspending | — | $133,990 | Jan 10, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE GOAL IS FOR DR. TIMOTHY WILESN WILL BE UTILIZING ALREADY COLLECTED DATA AS WELL AS ONGOING LONGITUDINAL DATA THAT IS BEING COLLECTED. THE MGH WILL COORDINATE EFFORTS WITH THE U OF M AND TEXAS TO SUPPLEMENT THE MTF AND NSDUH EXISTING EPIDEMIOLOGICAL DATASETS FROM THEIR RESPECTIVE INSTITUTIONS WITH THE MGH CLINICAL HEAL PROJECT. SUBK00015591 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: MD Parent award description: A MOSAIC APPROACH FOR UNDERSTANDING STIMULANT USE, MISUSE AND USE DISORDER TRAJECTORIES View parent award on USAspending | — | $78,553 | Nov 7, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | RESEARCH - BASE FUNDING
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR
MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.
€¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND
HOSTING TRAINEES FROM COLLABORATING LABS.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA
SEQUENCING.
SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL:
€¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. 109786.5110779 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $45,980 | Oct 19, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT A: VACCINE CENTER SUB00002149 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: GA Parent award description: COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU View parent award on USAspending | — | $117,900 | Oct 12, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THE SCOPE OF THE WORK IS TO MEASURE NEUTRALIZATION ACTIVITY OF SERUM OBTAINED FROM NURSING HOME RESIDENTS WHO HAVE RECEIVED COVID-19 VACCINES. THE SUBCONTRACTOR WILL UTILIZE AN EXTENSIVELY VALIDATED HIGH-THROUGHPUT MICRO-NEUTRALIZATION ASSAY TO OBTAINED PRECISE INHIBITORY CONCENTRATION MEASUREMENTS FOR EACH SAMPLE PROVIDED BY THE CONSORTIUM. THESE WILL BE PERFORMED IN DUPLICATE OR QUADRUPLICATE AS REQUIRED BY THE PRINCIPAL INVESTIGATORS. THE SUBCONTRACTOR WILL CLONE, PRODUCE AND CHARACTERIZE PSEUDOVIRUS BEARING THE SPIKE PROTEIN ENCODED BY CURRENTLY ADMINISTERED SARS-COV-2 VACCINES. THEY WILL ALSO PRODUCE PSEUDOVIRUS HARBORING SARS-COV-2 VARIANT SPIKE PROTEINS, REPRESENTING STRAINS THAT ARE CURRENTLY CIRCULATING GLOBALLY. THE SUBCONTRACTOR WILL ALSO CREATE NOVEL SARS-COV-2 PSEUDOVIRUSES ENCODING SPIKE PROTEINS BASED ON THE GENETIC SEQUENCE OBSERVED FOR THE S GENE IN BREAKTHROUGH INFECTIONS DETECTED IN VACCINATED NURSING HOME RESIDENTS AND USE THESE NOVEL REAGENTS TO DETERMINE THE INHIBITORY CONCENTRATION OF A SUBSET OF THE TOTAL SERUM SAMPLES AGAINST THESE NOVEL VARIANTS. THE SUBCONTRACTOR WILL ANALYZE DATA OBTAINED DURING EXECUTION OF THIS WORK, AND PROVIDE THESE TO THE CONSORTIUM AS REQUESTED AND PARTICIPATE IN THE WRITING OF MANUSCRIPTS DESCRIBING THESE RESULTS. 00001855 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541712 Parent award performance state: RI Parent award description: SHEPHERD 2021 DOMAIN 3-C001 View parent award on USAspending | HHSD200201691773IUSAspending | $417,500 | Sep 15, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | SUBRECIPIENT LAB WILL PERFORM SYSTEMS SEROLOGY ASSAYS TO EVALUATE THE IMMUNE RESPONSES
ELICITED IN 30 ADULTS IN A CONTROLLED HUMAN INFECTION MODEL (CHIM) STUDY BEFORE AND AFTER PERTUSSIS
CHALLENGE AND OVER MULTIPLE TIME POINTS. THESE ASSAYS WILL INCLUDE ANTIBODY BIOPHYSICAL PROFILING,
ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS BY VARIOUS PHAGOCYTES, ANTIBODY MEDIATED CYTOTOXICITY,
ANTIBODY MEDIATED COMPLEMENT ACTIVATION, AND ANTIBODY MEDIATED ANTI-MICROBIAL ACTIVITY. THE DATA
GENERATED FROM THESE HIGH THROUGHPUT STUDIES WILL THEN BE ANALYZED USING MACHINE LEARNING
APPROACHES. 20974-KB 2828 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541690 Parent award performance state: MD Parent award description: BAA TOPIC 22.3 - SYSTEMS SEROLOGY AND CELLULAR MARKERS OF PROTECTION AGAINST PERTUSSIS IN A CONTROLLED HUMAN INFECTION MODEL View parent award on USAspending | — | $294,000 | Jul 11, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT A: VACCINE CENTER SUB00002149 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: GA Parent award description: COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU View parent award on USAspending | — | $172,000 | Feb 28, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT A: VACCINE CENTER SUB00002149 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: GA Parent award description: COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU View parent award on USAspending | — | $172,000 | Feb 28, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM
THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109785.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $0 | Nov 17, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | TEST PHASE 2 AND PHASE 3 CLINICAL SAMPLES FROM AN RSV VACCIN 0000858462 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541713 Parent award performance state: OH Parent award description: DEEP ANTIBODY PROFILING FOR RSV INFECTION AND VACCINATION View parent award on USAspending | 75N93018D00013USAspending | $357,045 | Sep 19, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE GOAL IS FOR DR. TIMOTHY WILESN WILL BE UTILIZING ALREADY COLLECTED DATA AS WELL AS ONGOING LONGITUDINAL DATA THAT IS BEING COLLECTED. THE MGH WILL COORDINATE EFFORTS WITH THE U OF M AND TEXAS TO SUPPLEMENT THE MTF AND NSDUH EXISTING EPIDEMIOLOGICAL DATASETS FROM THEIR RESPECTIVE INSTITUTIONS WITH THE MGH CLINICAL HEAL PROJECT. SUBK00015591 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: MD Parent award description: A MOSAIC APPROACH FOR UNDERSTANDING STIMULANT USE, MISUSE AND USE DISORDER TRAJECTORIES View parent award on USAspending | — | $183,220 | Sep 8, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE SCOPE OF THE WORK IS TO MEASURE NEUTRALIZATION ACTIVITY OF SERUM OBTAINED FROM NURSING HOME RESIDENTS WHO HAVE RECEIVED COVID-19 VACCINES. THE SUBCONTRACTOR WILL UTILIZE AN EXTENSIVELY VALIDATED HIGH-THROUGHPUT MICRO-NEUTRALIZATION ASSAY TO OBTAINED PRECISE INHIBITORY CONCENTRATION MEASUREMENTS FOR EACH SAMPLE PROVIDED BY THE CONSORTIUM. THESE WILL BE PERFORMED IN DUPLICATE OR QUADRUPLICATE AS REQUIRED BY THE PRINCIPAL INVESTIGATORS. THE SUBCONTRACTOR WILL CLONE, PRODUCE AND CHARACTERIZE PSEUDOVIRUS BEARING THE SPIKE PROTEIN ENCODED BY CURRENTLY ADMINISTERED SARS-COV-2 VACCINES. THEY WILL ALSO PRODUCE PSEUDOVIRUS HARBORING SARS-COV-2 VARIANT SPIKE PROTEINS, REPRESENTING STRAINS THAT ARE CURRENTLY CIRCULATING GLOBALLY. THE SUBCONTRACTOR WILL ALSO CREATE NOVEL SARS-COV-2 PSEUDOVIRUSES ENCODING SPIKE PROTEINS BASED ON THE GENETIC SEQUENCE OBSERVED FOR THE S GENE IN BREAKTHROUGH INFECTIONS DETECTED IN VACCINATED NURSING HOME RESIDENTS AND USE THESE NOVEL REAGENTS TO DETERMINE THE INHIBITORY CONCENTRATION OF A SUBSET OF THE TOTAL SERUM SAMPLES AGAINST THESE NOVEL VARIANTS. THE SUBCONTRACTOR WILL ANALYZE DATA OBTAINED DURING EXECUTION OF THIS WORK, AND PROVIDE THESE TO THE CONSORTIUM AS REQUESTED AND PARTICIPATE IN THE WRITING OF MANUSCRIPTS DESCRIBING THESE RESULTS. 00001855 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541712 Parent award performance state: RI Parent award description: SHEPHERD 2021 DOMAIN 3-C001 View parent award on USAspending | HHSD200201691773IUSAspending | $307,246 | Aug 24, 2022 | — – — |
| Subcontractor | Department of Defense | INTEGRATED CLINICAL ENVIRONMENT 156086 Parent award context Parent award agency: Department of Defense · Defense Contract Management Agency Parent award NAICS: 541712 Parent award performance state: MD Parent award description: MEDICAL DEVICE AUTONOMY View parent award on USAspending | N0002413D6400USAspending | $170,626 | Jun 29, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | RESEARCH - BASE FUNDING
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR
MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.
€¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND
HOSTING TRAINEES FROM COLLABORATING LABS.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA
SEQUENCING.
SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL:
€¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. 109786.5110779 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $1,095,397 | May 2, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM
THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109785.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $724,129 | May 2, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | RESEARCH - BASE FUNDING
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR
MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.
€¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND
HOSTING TRAINEES FROM COLLABORATING LABS.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA
SEQUENCING.
SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL:
€¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. 109786.5110779 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $877,061 | Apr 25, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM
THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109785.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $52,157 | Apr 11, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | YEAR 1 SITE RESPONSIBILITIES:
KICKOFF MEETING (BY TELECONFERENCE)
O TWO HOURS
O JUSTIFICATION: REQUIRED FOR COMMUNICATION OF PROJECT GOALS AND EXPECTATION
ESTABLISHMENT OF THE SURVEILLANCE PROTOCOL AND CASE REPORT FORM INCLUDING RUDIMENTARY TEXT IDENTIFICATION FOR VACCINATION STATUS.
INFORMATION TRANSFER FROM EACH SITE FOR ALL GOALS, WHICH REQUIRES FACE TO FACE MEETINGS, MULTIPLE ZOOM CALLS WITH THE PRIME SITE, AND MULTIPLE TEST RUNS. REQUIRED TO COMMUNICATE WITH OTHER SITES TO BALANCE FEASIBILITY AND RIGOR.
ESTABLISH OR AMEND AGREEMENTS WITH EDNS
REPORT ESTIMATES OF POPULATIONS SERVED BY EACH HOSPITAL/HOSPITAL NETWORK.
O JUSTIFICATION: REQUIRES SEVERAL MEETINGS TO ESTABLISH SEARCH PARAMETERS AND REVIEW RESULTS.
IRB APPROVAL OF THE SURVEILLANCE PROTOCOL.
O 20 HOURS. PROTOCOL PREPARATION, SUBMISSION AND REVISION
O JUSTIFICATION: FOR ALL GOALS, EACH SITE WILL NEED TO MAINTAIN IDENTIFYING INFORMATION ON EACH PATIENT, AND THIS WILL REQUIRE FULL IRB REVIEW. DEVELOP OR MODIFY EXISTING DATA COLLECTION TOOLS AND PROTOCOLS TO SUPPORT THE DATA COLLECTION.
O JUSTIFICATION: REQUIRED TO ESTABLISH FEASIBILITY OF ENSURING COMPLIANCE WITH FEDERAL RULES ON PRIVACY, WHILE ALLOWING LOCAL IDENTIFICATION, AND ENSURING INTERNAL SYSTEMS FOR SWAB TRANSFER TO APPROPRIATE AUTHORITIES.
SUBMIT DRAFT DATA MANAGEMENT PLAN
O JUSTIFICATION: TWO ONE-HOUR ZOOM CALLS TO CREATE METHODS OF API EXTRACTION, DEFINITIONS OF DATA QUALITY, METHODOLOGY FOR TRAINING OF ABSTRACTORS FOR GOAL [6], METHODS FOR REAL TIME DATA COLLECTION IN GOAL [4], AND PROCEDURES FOR HANDLING OF MISSING DATA.
WEEKLY API MAINTENANCE, UPDATING AND TROUBLESHOOTING, PRE-EXPORT DATA REVIEW, CLEANING AND VERIFICATION AND EXPORT TO REDCAP.
GOAL [2-3]:
INITIAL SETUP-RUDIMENTARY WEEKLY
TRACKING OF THE SWAB TRANSFERS TO LOCAL/STATE HEALTH DEPARTMENTS.
CASE ACQUISITION, STRING VARIABLE AND CHART REVIEW AND DATA ENTRY FOR 5400 CASES PER YEAR. THE MAXIMUM NUMBER OF INDIVIDUAL PATIENTS REVIEWED AT
EACH SITE FOR THIS PURPOSE WILL BE CAPPED AT 5400. WSU22011 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541360 Parent award performance state: GA Parent award description: ENHANCING U.S. SURVEILLANCE OF LABORATORY CONFIRMED SARS-COV-2, INFLUENZA, AND OTHER RESPIRATORY VIRUSES View parent award on USAspending | — | $235,237 | Mar 16, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | €œAPPLIED RESEARCH TO ADDRESS THE CORONAVIRUS (COVID-19) CONTINUED PUBLIC HEALTH EMERGENCY €€Œ DEVELOPING
STRATEGIES FOR PROTECTION, PREVENTION & CONTROL IN COMMUNITIES€Ͽ½ 5000855-5500001509 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541714 Parent award performance state: MA Parent award description: REAL TIME SARS COV-2 View parent award on USAspending | — | $440,592 | Feb 3, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
RESEARCH - BASE FUNDING
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.
€¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND HOSTING TRAINEES FROM COLLABORATING LABS.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING.
SPECIFICALLY, FOR THE "OPTIONAL STUDIES"
PROJECT 1 SIV-BCG IV' SUBRECIPIENT WILL:
€¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. 109786.5110779 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $0 | Nov 9, 2021 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
DESCRIPTION:
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.
SPECIFICALLY, SUBRECIPIENT WILL:
€¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY.
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. 109785.5110777 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $0 | Nov 9, 2021 | — – — |
| Subcontractor | Department of Health and Human Services | THE SCOPE OF THE WORK IS TO MEASURE NEUTRALIZATION ACTIVITY OF SERUM OBTAINED FROM NURSING HOME RESIDENTS WHO HAVE RECEIVED COVID-19 VACCINES. THE SUBCONTRACTOR WILL UTILIZE AN EXTENSIVELY VALIDATED HIGH-THROUGHPUT MICRO-NEUTRALIZATION ASSAY TO OBTAINED PRECISE INHIBITORY CONCENTRATION MEASUREMENTS FOR EACH SAMPLE PROVIDED BY THE CONSORTIUM. THESE WILL BE PERFORMED IN DUPLICATE OR QUADRUPLICATE AS REQUIRED BY THE PRINCIPAL INVESTIGATORS. THE SUBCONTRACTOR WILL CLONE, PRODUCE AND CHARACTERIZE PSEUDOVIRUS BEARING THE SPIKE PROTEIN ENCODED BY CURRENTLY ADMINISTERED SARS-COV-2 VACCINES. THEY WILL ALSO PRODUCE PSEUDOVIRUS HARBORING SARS-COV-2 VARIANT SPIKE PROTEINS, REPRESENTING STRAINS THAT ARE CURRENTLY CIRCULATING GLOBALLY. THE SUBCONTRACTOR WILL ALSO CREATE NOVEL SARS-COV-2 PSEUDOVIRUSES ENCODING SPIKE PROTEINS BASED ON THE GENETIC SEQUENCE OBSERVED FOR THE S GENE IN BREAKTHROUGH INFECTIONS DETECTED IN VACCINATED NURSING HOME RESIDENTS AND USE THESE NOVEL REAGENTS TO DETERMINE THE INHIBITORY CONCENTRATION OF A SUBSET OF THE TOTAL SERUM SAMPLES AGAINST THESE NOVEL VARIANTS. THE SUBCONTRACTOR WILL ANALYZE DATA OBTAINED DURING EXECUTION OF THIS WORK, AND PROVIDE THESE TO THE CONSORTIUM AS REQUESTED AND PARTICIPATE IN THE WRITING OF MANUSCRIPTS DESCRIBING THESE RESULTS. 00001855 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541712 Parent award performance state: RI Parent award description: SHEPHERD 2021 DOMAIN 3-C001 View parent award on USAspending | HHSD200201691773IUSAspending | $172,202 | Nov 2, 2021 | — – — |
| Subcontractor | Department of Health and Human Services | LITERATURE REVIEW, ENVIRONMENTAL SCAN, AND ANALYSIS OF SECONDARY DATA. 53100 · Prime awardUSAspending | HHSD2002013M53890BUSAspending | $182,202 | Oct 20, 2021 | — – — |
| Subcontractor | Department of Health and Human Services | SYSTEMS SEROLOGY TO PROFILE ALL COHORTS AND ANIMALS STUDIES TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING CONTROL OF AND PROTECTION FROM INFLUENZA INFECTION. SUB00002149 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: GA Parent award description: COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU View parent award on USAspending | — | $250,000 | Oct 16, 2021 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced
- Department of Veterans AffairsGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.